This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We would like to raise 2 issues in response to the article reporting results of the Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) trial by Dr Schömig and colleagues.¹ First, the use of abciximab before PCI in patients with acute MI within 12 hours of symptom onset has been shown to reduce the 30-day incidence of death and MI, and this benefit is independent of the type of device used during the procedure.² Given this, abciximab alone could have accounted for the reduction in infarct size found in these patients rather than combined effect of abciximab and primary PCI. In addition, the absence of benefit for the secondary clinical end points suggests that an effect modification may have occurred between the 2 modes of therapy among the patients in the intensive treatment group.

Second, the criteria set for the secondary end point of recurrent MI could have . . . [Full Text of this Article]

Balavenkatesh Kanna, MD, MPH
bvkanna@aol.com

Rami Almadi, MD
Lincoln Medical and Mental Health Center
New York, NY

RELATED ARTICLES

Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction
Stanley A. Rubin and Alberta L. Warner
JAMA. 2005;294(16):2030-2031.
EXTRACT | FULL TEXT  

Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction—Reply
Albert Schömig, Gjin Ndrepepa, and Adnan Kastrati
JAMA. 2005;294(16):2031-2032.
EXTRACT | FULL TEXT